NewsBenzinga보스턴 프로퍼티스, 3분기 FFO 1.89달러로 예상치 1.80달러 상회, 매출 9억 1,143만 1천 달러로 예상치 8억 9,610만 1천 달러 상회 보스턴 프로퍼티스, 3분기 FFO 1.89달러로 예상치 1.80달러 상회, 매출 9억 1,143만 1천 달러로 예상치 8억 9,610만 1천 달러 상회 Benzinga 2026.10.27 20:06 (GMT+0) Open on Benzinga Other news Pharming Receives U.K. Approval For Joenja In Children Aged 4 To 11 With APDS, Supported By Pediatric Clinical Program Data; Marks Step In Expansion Across Age Groups And Markets Molecular Partners Says MP0632 Preclinical Data At SITC 2026 Show No Detectable Impact On Healthy Mesothelial Or Epithelial Cells, Supporting IND-Enabling Studies In MSLN And EpCAM Solid Tumors Reported Earlier, Perspective Therapeutics Says Bamzireotide Delivers 37% ORR In All 68 Treated NET Patients, 91% Disease Control, Median Follow-Up Up To 128 Weeks; Grade 3 TEAEs In 29%, No Grade 4 Or 5 Events Reported Earlier, FDA Grants J&J Accelerated Approval For Rybrevant Faspro In Advanced Head And Neck Squamous Cell Carcinoma, Based On OrigAMI-4 Phase 1b/2 Trial Showing 42% Overall Response Rate Stock Market: Will S&P 500 Open Up or Down Today? IREN Mining Revenue Falls 58% as AI Sales Reach $200 Million
Pharming Receives U.K. Approval For Joenja In Children Aged 4 To 11 With APDS, Supported By Pediatric Clinical Program Data; Marks Step In Expansion Across Age Groups And Markets
Molecular Partners Says MP0632 Preclinical Data At SITC 2026 Show No Detectable Impact On Healthy Mesothelial Or Epithelial Cells, Supporting IND-Enabling Studies In MSLN And EpCAM Solid Tumors
Reported Earlier, Perspective Therapeutics Says Bamzireotide Delivers 37% ORR In All 68 Treated NET Patients, 91% Disease Control, Median Follow-Up Up To 128 Weeks; Grade 3 TEAEs In 29%, No Grade 4 Or 5 Events
Reported Earlier, FDA Grants J&J Accelerated Approval For Rybrevant Faspro In Advanced Head And Neck Squamous Cell Carcinoma, Based On OrigAMI-4 Phase 1b/2 Trial Showing 42% Overall Response Rate
